All G's LFX Brings Commercial-Scale Apo-Lactoferrin to the US Market

All G, an Australian precision-fermentation biotechnology company, announced the US launch of LFX, describing it as the first commercially available apo-lactoferrin.¹

The ingredient carries generally recognized as safe status and has received an FDA "no questions" letter for use in adult nutrition, and is being positioned for dietary supplement, functional food, and beverage formulations targeting active nutrition, gut health, healthy aging, women's health, and immune support.

For manufacturers sourcing lactoferrin, the launch addresses a supply-side gap, which is consistent, at-scale access to the low-iron form of the protein. "Lactoferrin's ability to regulate iron is what drives many of its most valuable benefits," said Jared Raynes, PhD, All G’s chief scientific officer. "When lactoferrin's iron-binding sites are already occupied, functionality becomes lessened. We are changing that with LFX by making the iron-free apo form commercially available at scale for the first time."¹

What Is Apo-Lactoferrin, and Why Does Iron Saturation Matter?

Lactoferrin's biological behavior is shaped substantially by iron saturation, the proportion of its iron-binding sites already occupied by iron. According to the company, LFX is manufactured at under 5% iron saturation, the threshold generally used to define apo-lactoferrin, compared with roughly 20% saturation typical of commercial dairy-derived lactoferrin and more than 80% for heavily iron-loaded holo-lactoferrin.¹

This mirrors the naturally low-iron state of lactoferrin found in human breast milk. A 2025 peer-reviewed review in the Journal of Agricultural and Food Chemistry describes iron saturation as a key determinant of the protein's structural and functional properties, noting that apo- and holo-lactoferrin exhibit distinct biological activity depending on saturation level.²

What Does the Research Say About Apo-Lactoferrin's Antimicrobial and Gut Health Effects?

The rationale behind apo-lactoferrin's antimicrobial function centers on iron sequestration. With binding sites open, the protein can capture free iron that bacteria depend on for growth, in principle limiting pathogen proliferation.

That mechanism is supported in general terms by the broader lactoferrin literature, but its effects are not uniform across pathogens. A 2016 study using a human in vitro gut model found that holo-lactoferrin, not apo-lactoferrin, delayed Clostridioides difficile growth and prevented toxin production, with the researchers noting the inhibitory effect appeared to be iron independent.³ That finding illustrates that iron saturation's effect on antimicrobial performance depends on the specific pathogen and mechanism involved, rather than uniformly favoring the apo form.

How Does LFX Fit Into the Current Lactoferrin Supply Landscape?

Lactoferrin has drawn manufacturer interest for immune health, iron regulation, and gut health formulations, but sourcing has historically been constrained by dependence on dairy processing byproducts and inconsistent iron saturation across batches.

All G reports producing LFX through precision fermentation at a scale of multiple metric tons annually, independent of dairy production, with greater than 95% purity and batch-to-batch consistency.¹ "There is tremendous interest from companies looking to formulate with the apo form of lactoferrin because it offers a level of scientific differentiation in mirroring the naturally low-iron form of lactoferrin," noted Isidoor Maljers, business development manager at All G.¹

References

1. All G. All G launches LFX in the US - the first commercially available apo-lactoferrin delivering the protein's full biological potential. July 22, 2026. Accessed July 23, 2026. Press release provided via email.

2. Huang Y, Tao Y, Yang H, et al. Critical importance of iron saturation in lactoferrin: effects on biological activity, nutritional functions, and applications. J Agric Food Chem. 2025;73(18):10665-10680. doi:10.1021/acs.jafc.4c11535

3. Chilton CH, Crowther GS, Śpiewak K, et al. Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection. J Antimicrob Chemother. 2016;71(4):975-985. doi:10.1093/jac/dkv452